Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10p -0.75% 13.15p 12.80p 13.50p 13.25p 13.15p 13.25p 64,912 11:28:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.6 -6.9 -0.4 - 16.70

Omega Diagnostics Share Discussion Threads

Showing 2751 to 2774 of 2775 messages
Chat Pages: 111  110  109  108  107  106  105  104  103  102  101  100  Older
DateSubjectAuthorDiscuss
14/12/2018
13:34
Lol never expected to be here this long thought we would be at quid by now ! Happy Christmas and as del boy says next year we will all be millionaires
leedslad001
14/12/2018
11:48
Leeds, I don't think this was the Christmas surprise we were expecting, good to see the short term shareholder value working well.......LOL
barrywhit
12/12/2018
12:46
There is a difference between trust and confidence - I can understand why you may have lost confidence ( although since Colin was appointed he has delivered on the plan outlined) there is no basis for the lack of trust comment - I would trust all of my former colleagues with the keys to my house. They are honest hardworking and trustworthy.
nxc
12/12/2018
11:49
Time will tell Arthur, but at 13p share price my SIPP looks pretty sad..unfortunately the company have lost the trust of small P.I's over the last 12 - 18months and it is those people that move the share price......
barrywhit
12/12/2018
11:39
Hi Barry, i've also emailed Kieron Harbinson in the past and he replied very promptly. I think this is a very attractive risk reward situation at these prices, I still believe the Food Intolerance business is worth the market cap on its own with CD4 thrown in for free.
arthur_lame_stocks
12/12/2018
11:05
Thanks for you feed back Arthur, I am still a holder with 95% in my SIPP. I have had dialogue with Kieron Harbinson over the last 18 months and am also happy to hold until CD4 comes to fruition...
barrywhit
12/12/2018
10:59
I did phone David Evans and had a perfectly civil chat with him. I recommend others do it, he was pretty open as much as he can be without breaking market rules. I put the phone down feeling that there is still a lot to play for and my reasons for continuing to hold are sound. The big opportunity appears to be CD4 and I think this is where resources will be concentrated going forward; millions of tests a year at $5 a pop and 60% gross margins, if they pull that off then today's share rpice is going to look a bargain.
arthur_lame_stocks
12/12/2018
09:37
Arthur - happy to take your call
nxc
12/12/2018
08:54
Shareholding information last updated as at 18 October 2018 The number of shares in issue is 126,959,060. The percentage of shares not in public hands at 18 October 2018 is 44.59%. There are no shares held as treasury shares. There are no restrictions on the transfer of the Company's AIM securities Significant Shareholders Richard Sneller 25,430,710 20.03% Legal & General Investment Management 15,857,031 12.49% Oryx International Growth Fund Ltd 14,096,692 11.10% Hargreaves Lansdown Stockbrokers 6,940,972 5.47% Octopus Investments Limited 6,682,730 5.26% Unicorn Asset Management 4,266,750 3.36% David Evans 4,154,745 3.27% Mobeus Equity Partners LLP 3,999,950 3.15% Interactive Investor 3,952,832 3.11%
barrywhit
12/12/2018
00:46
David, one thing that is a consequence of the internet, and maybe modern life, is that information is available at all times and people seem to expect instant gratification from whatever it is. If you read these boards you'll realise that blaming management when the share price falls or things don't work out the way people want quickly enough is par for the course. In ODX's case it does look as though mistakes were made and the company overextended itself given its limited resources. I remain a shareholder because I still believe that the market price doesn't reflect the intrinsic value in the food intolerance business and the opportunity from CD4. I also think the company will be broken up in the medium term and the value realised. Chris Mills has form on this front but I don't know what Sneller's angle is. I may give you a bell tomorrow, I guarantee i'll be civil and i'll give you my name so you know who I am if i'm not but any more information you can give me would be much appreciated.
arthur_lame_stocks
11/12/2018
20:43
I am and I am happy to leave it there Barry - my number is readily accessible from other press releases - I put it there to enable those who had genuine queries I could answer them and for the vexatious that they could vent their spleen directly at me without the anonymity that this and other bulletin boards offer.
nxc
11/12/2018
20:12
NXC, if you really are David Evans I would remove your mobile number from the thread. there are some strange people that frequent ADVFN.....You really shouldn't leave your number on the thread.....
barrywhit
11/12/2018
18:12
I personally don't think the ex Non-Exec Chairman's 4+ million shares is an issue as David Evans holds 42% of his ODX shares in his SIPP and in any case the share price has only decreased under his stewardship so I cannot see why he would want to offload but maybe he will if Sneller and/or Mills want to grab a few more, which might just make it a good idea if he did! 🤔
hyperboreus
11/12/2018
12:52
In June 2016 Evans said: “We are evaluating all these opportunities, including those which could be delivered from existing resources, to ensure we are on the right side of under-promising and over-delivering.R21; Since then they have over-promised and under-delivered seemingly at every opportunity. It’s right the executives are held to account for misleading investors. As far as I’m concerned, either Evans was too weak to do that or this was a pipe and slippers job for him. At any rate I think it’s good he’s gone. It’s a pity the broom that moved Shepherd under the carpet didn’t sweep Evans and Harbinson away at the time.
gwr7
10/12/2018
14:59
Director move Enter stage right ... Ian
buywell3
10/12/2018
14:44
What will Evans do with his 4m plus shares?????
barrywhit
10/12/2018
11:54
On 30th November Evans said: Rest assured we will continue to work towards achieving success for all our stakeholders." A week later he's slung his hook. Foresight was never a feature of his updates.
gwr7
10/12/2018
11:39
I got the impression Shepherd was getting money for old rope here. His last missive was clueless. If Harbinson goes as well things will be looking up. He looks like an FD who is numerically challenged. I take it he sanctioned the expenditure on the Indian debacle.
gwr7
10/12/2018
11:18
The Chairman finally going this morning after 18 years of presiding over zero increase in shareholder value is a further much needed sign of change . Perhaps his rather vague and uncertain interim statement only a week ago was the last straw . For sure , one is now more inclined to believe the more upbeat quotes coming from the CEO and FD in the two press articles that have been posted here . This may also be a sign of impatience by the activist shareholder element , Sneller and Miller , who together now speak for 31% of Omega . Perhaps they will want to see an established and reputable outsider to be appointed as Chairman ?
bomber13
07/12/2018
18:03
So it all comes down to '' probably '' , '' hopefully '', ''projected sales'' and dealing with Nigeria ? Is Nigeria the main target market ? I note Zimbabwe comes after Nigeria ... so is that the second target country for ''projected sales'' Who is guiding who here ?
buywell3
07/12/2018
17:56
buywell3, the market was expecting/hoping to see some projected sales figures for CD4 but they probably wont be available until Feb/March time after the Nigeria meeting/evaluation....then hopefully the share price will improve....
barrywhit
07/12/2018
17:09
Can anyone please put this into simple English and explain what this means ? He added: "I’m obviously speculating but my impression is that the markets were expecting us to guide on CD4 and obviously we haven’t given guidance there so there may be a little bit of disappointment on not guiding on CD4 but clearly what we want to do is when we do guide we get the numbers."
buywell3
07/12/2018
16:53
Many thanks Rivaldo, it reads very well for the New Year...
barrywhit
07/12/2018
15:34
Big interview with the CEO - I'll paste it in full if you don't mind as access to the Herald's content is limited to only two articles per month. Note that the CD4 update is coming within a month or so: Https://www.heraldscotland.com/business_hq/17272806.shares-drop-14-as-omegas-hiv-test-guidance-delayed/ " Colin King, Omega chief executive, above, said: "Our results are where we expected them to be. "Obviously over the last six months we’ve gone through a period of restructuring the business. "I’m pleased with how that’s going, and once we get that clear it allows us to completely focus on our key growth areas, which are food, allergy and our CD4 test. "In terms of progress in those three areas, again I’m pleased with the progress we are making. "Where we do expect to see significant revenue uplift is with CD4. "In terms of CD4, we have two products, the 350 test which is used as a gatekeeper for starting treatment for HIV patients. "We are targeting the countries where we believe that test will be adopted." Read more: Scottish biotechnology firm hails progress made with HIV test Progress is being made in Nigeria and Zimbabwe. He added: "Both countries are in the process of doing an in-country evaluation and we expect them to be completed during January or February time, so we expect the first commercial order for CD4 to Nigeria in February or March, so that is great news. "At this stage we had hoped to give a bit of guidance on what that would look like. "Unfortunately we don’t have that just yet - we are still running through that with our partner. "There is a key meeting next week in Nigeria and we will get a better feel for what that will look like when our meeting is concluded. "But we do expect it to be significant for us. "Where we see the higher potential is in the advanced disease test (the second CD4 product) that we are developing. "Overall we are making good progress there." He said: "Probably the biggest challenge is where you can’t fully control your own destiny where you are working with other countries and they have to go through in-country evaluations, you always wish these things would go quicker than they do. "They will happen, it is just more a case of timing that is probably the biggest frustration there." He added: "I’m obviously speculating but my impression is that the markets were expecting us to guide on CD4 and obviously we haven’t given guidance there so there may be a little bit of disappointment on not guiding on CD4 but clearly what we want to do is when we do guide we get the numbers." "By Christmas or early New Year we hopefully will be giving that guidance and hopefully that will get the share price back up again." Kieron Harbinson, Omega finance director, said: "The overall message is that we’ve re-shaped the business, we are a leaner outfit and we’ve got three key product areas to focus on that can deliver growth." Analysts at house broker FinnCap said the interim results were "in line with the October trading update, albeit complicated by the disposal of its legacy infectious diseases business, closure of loss-making German and Indian operations and exceptional profits/write-backs" and made no changes to its full year forecast which assumes an adjusted pre-tax profit of £200,000 in the second half."
rivaldo
Chat Pages: 111  110  109  108  107  106  105  104  103  102  101  100  Older
Your Recent History
LSE
ODX
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181214 14:21:48